# US 2024/0391969 A1 · Methods and compositions to spread protein cargoes across multi-nucleated cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0391969 A1
- Document ID: US20240391969A1
- Status: Published application
- Kind: A1
- Application number: 17/927,337
- Filed: 2021-05-21
- Published: 2024-11-28
- Earliest claimed: 2020-05-22
- Assignees: University of Florida Research Foundation, Inc.
- Applicants: University of Florida Research Foundation, Incorporated
- Inventors: Eric Tzy-Shi Wang; Keril K. Poukalov
- Web page: https://patentgrep.com/patent/US20240391969A1

## CPC

- C07K 14/4707: {Muscular dystrophy}
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C12N 15/86: Viral vectors
- C07K 2319/09: containing a nuclear localisation signal
- C07K 2319/095: containing a nuclear export signal
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods and compositions useful for delivering a protein to a plurality of nuclei in a cell. Fusion proteins comprising one or more signals useful for promoting delivery of the proteins to a plurality of nuclei in a multinucleate cell. Methods comprising administering isolated nucleic acids to a multinucleate cell, wherein the isolated nucleic acid comprises a sequence encoding a fusion protein, the fusion protein comprising, a protein of interest fused to at least the following migration signals: (a) at least one nuclear export signal (NFS); and (b) at least one nuclear localization signal (NLS) and/or at least one nucleolar localization signal (NoLS). Fusion proteins comprising: (a) a protein of interest; and (b) at least the following migration signals: (i) a nuclear export signal (NFS); (ii) a nuclear localization signal (NLS); and (iii) a nucleolar localization signal (NoLS). Methods of making and using the same. Methods of delivering recombinant genes and/or fusion proteins to multinucleate cells.

## Claims

### Claim 1

A method comprising administering an isolated nucleic acid to a multinucleate cell, wherein the isolated nucleic acid comprises a sequence encoding a fusion protein, the fusion protein comprising, a protein of interest fused to at least the following migration signals:
(a) at least one nuclear export signal (NES); and
(b) at least one nuclear localization signal (NLS) and/or at least one nucleolar localization signal (NoLS),
optionally, wherein the isolated nucleic acid encodes an amino acid sequence comprising a sequence with at least 70% identity to SEQ ID NO: 13.

### Claim 2 (depends on 1)

The method of claim 1, wherein the fusion protein further comprises at least one additional migration signal, wherein the additional migration signal may be identical or distinct from the migration signals used in claim 1, or wherein the fusion protein further comprises at least two additional migration signals, wherein the additional migration signals may be identical or distinct from the migration signals used in claim 1.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the isolated nucleic acid encodes a fusion protein wherein at least one of the migration signals is positioned at the C-terminus of the protein of interest or at the N-terminus of the protein of interest.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the protein of interest is a therapeutic protein, a nuclear protein, or at least one of the following: a transcriptional factor, a transcriptional repressor, an RNA binding protein, a DNA modifying protein, a DNA editing protein, and a Cas protein.

### Claim at position 7

-8. (canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the protein of interest is DUX4, or a variant thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the protein of interest carries RNA.

### Claim 11 (depends on 1)

The method of claim 1, wherein the protein of interest is used to treat Facioscapulohumeral dystrophy.

### Claim 12 (depends on 1)

The method of claim 1, wherein the isolated nucleic acid is flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs).

### Claim 13 (depends on 1)

The method of claim 1, wherein the multinucleate cell is a skeletal muscle cell.

### Claim 14 (depends on 1)

The method of claim 1, wherein the multinucleate cell is a liver cell.

### Claim 15 (depends on 1)

The method of claim 1, wherein the nucleic acid is administered to a subject, optionally wherein the subject is mammalian.

### Claim 16 (depends on 1)

The method of claim 1, wherein the subject has a disorder, optionally wherein the disorder is Facioscapulohumeral dystrophy.

### Claim at position 16

-21. (canceled)

### Claim 22

A fusion protein comprising:
(a) a protein of interest; and
(b) at least the following migration signals:
(i) a nuclear export signal (NES);
(ii) a nuclear localization signal (NLS); and
(iii) a nucleolar localization signal (NoLS),
optionally, wherein the fusion protein comprises a sequence with at least 70% identity to SEQ ID NO: 13.

### Claim at position 18

-26. (canceled)

### Claim 27 (depends on 22)

The fusion protein of claim 22, wherein at least one of the migration signals is linked to the protein of interest via a linker.

### Claim 28 (depends on 22)

The fusion protein of claim 22, wherein at least one of the migration signals comprises a sequence with at least 95% identity to any one of SEQ ID NO: 1-6 or 14-570.

### Claim 29 (depends on 22)

The fusion protein of claim 22, wherein at least one of the migration signals comprises a sequence with at least 95% identity to SEQ ID NO: 3.

### Claim 30 (depends on 22)

The fusion protein of claim 22, wherein at least one of the migration signals comprises a sequence of SEQ ID NO: 1.

### Claim 31 (depends on 22)

The fusion protein of claim 22, wherein at least one of the migration signals comprises a sequence of SEQ ID NO: 3.

### Claim at position 24

-33. (canceled)

### Claim 34 (depends on 22)

An isolated nucleic acid comprising a nucleic acid sequence encoding the fusion protein of claim 22.

### Claim at position 26

-40. (canceled)

### Claim 41 (depends on 34)

A recombinant adeno-associated virus (rAAV), comprising:
(a) the isolated nucleic acid of claim 34 flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs); and
(b) an AAV capsid protein.

### Claim at position 28

-56. (canceled)
